GYRE (Gyre Therapeutics) Notes Receivable: $3.8 Mil (As of Mar. 2026)


GYRE Gyre Therapeutics Inc GYRE
39 GF Score
Price $6.69
GF Value $9.82
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Gyre Therapeutics Notes Receivable?

Gyre Therapeutics GYRE +3.56% 39 Notes Receivable is $3.8 Mil as of Mar. 2026. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.82 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Gyre Therapeutics's Notes Receivable for the quarter that ended in Mar. 2026 was $3.8 Mil.

Gyre Therapeutics's quarterly Notes Receivable increased from Sep. 2025 ($0.69 Mil) to Dec. 2025 ($5.64 Mil) but then stayed the same from Dec. 2025 ($5.64 Mil) to Mar. 2026 ($3.82 Mil).

Gyre Therapeutics's annual Notes Receivable increased from Dec. 2023 ($0.39 Mil) to Dec. 2024 ($4.37 Mil) and increased from Dec. 2024 ($4.37 Mil) to Dec. 2025 ($5.64 Mil).

Gyre Therapeutics Notes Receivable Related Terms

Gyre Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Gyre Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics Notes Receivable Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 1.52 0.39 4.37 5.64

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.14 0.50 0.69 5.64 3.82
GYRE
39GF Score
Gyre Therapeutics Inc GYRE
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gyre Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $3.8 Mil mean?
Gyre Therapeutics (GYRE) has a Notes Receivable of $3.8 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Gyre Therapeutics and its competitors.
Is Gyre Therapeutics' Notes Receivable too high?
Gyre Therapeutics' current Notes Receivable is $3.8 Mil. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Notes Receivable compare to RLMD and ACRS?
Gyre Therapeutics' Notes Receivable of $3.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current Notes Receivable is $3.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.82, compared to a current price of $6.69 — trading 31.9% below its estimated fair value. The current Notes Receivable is $3.8 Mil. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Notes Receivable is $3.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $6.69 is trading 31.9% below its estimated GF Value™ of $9.82. GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.

Key valuation signals for GYRE:

  • Notes Receivable: $3.8 Mil
  • GF Value™: $9.82 vs. price of $6.69 (31.9% below fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score

Get the complete analysis for GYRE

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.69
Price
$9.82
GF Value